Dr. Pierre-Henri Benhamou
Dr. Pierre-Henri Benhamou co-founded DBV in 2002, and has served as Chief Executive Officer from 2002-2006 and 2010-present. He was appointed Chairman of the Board of Directors in March 2012. From 2006 to 2010, Dr. Benhamou served as Chief Scientific Officer of DBV. Along with Dr. Christophe Dupont and Bertrand Dupont, Pierre-Henri Benhamou invented and patented the epicutaneous method of immunotherapy and the Viaskin® technology. Before co-founding DBV, Dr. Benhamou was a practicing physician, specializing in pediatric gastroenterology, and has held numerous clinical and academic positions. In 2003, he received the Altran Foundation Prize for Innovation for his work on the development of diagnostic patch tests. Dr. Benhamou has published numerous papers, originated key scientific collaborations for DBV, and has been instrumental in forming the Company’s Scientific Advisory Board. Dr. Benhamou received an M.D. from Faculté de Médecine de Paris in 1984 and his specialization degree in Pediatrics in 1987.
David Schilansky serves as DBV’s Deputy Chief Executive Officer, responsible for enabling effective coordination of the Company’s operational and strategic imperatives, oversees the Executive Committee. Most recently, he was Chief Operating Officer and joined DBV as Chief Financial Officer in December 2011. David is also DBV’s principal financier. Previously, he held various senior positions at Ipsen, including Interim Chief Financial Officer. Earlier in his career, he was co-head of investor relations at Thomson S.A. (now Technicolor) and Associate at Warburg Dillon Read (now UBS) in the field of mergers and acquisitions. David Schilansky received a master’s degree from Université de Paris Dauphine and a post-graduate degree from Imperial College in London.
Charles Ruban serves as DBV’s Chief Operating Officer, overseeing Commercial Operations globally and responsible for aligning all Regulatory, Development and Manufacturing. He is a member of the Executive Committee. Charles Ruban joined DBV in 2012 as Chief Development Officer to lead all development activities; subsequently he was appointed President, North America and Chief Commercial Officer, overseeing North American Operations and supporting the US launch of Viaskin Peanut. Prior to DBV, from 2003 to 2012, Charles Ruban held various executive positions at Stallergenes S.A., including Senior Vice President of Product Development. From 1994 to 2003, he spent nine years at Eurogroup Consulting as a management and strategy consultant for international industrial clients, including healthcare companies. Charles Ruban received an Engineering degree from the Ecole Centrale de Lyon, trained at Harvard-MIT Division of Health Sciences and Technology for his Biomedical Engineering Master of Science, and received an Executive MBA from INSEAD.
Bertrand Dupont has served as Senior Executive Vice President, Technology since January 2015 and is in charge of the continued development of electrospray and upscaling of production tools. He is also a member of the Executive Committee. Dupont previously served as Chief Technical Officer from 2002-2015. From 1977 to 2002, Dupont served as a high school and university professor teaching mechanics and robotics. Since 2000, he has been at the core of the development of the Viaskin patch and its potential applications. Dupont is a key figure in the development of the Viaskin technology and application systems. He is responsible for every technical aspect of development around the Viaskin technology, including the design of the Viaskin patch, in-house industrial patch filling processes and the design and building of the machines developed by DBV Technologies. Dupont is also responsible for the production of the finished product in DBV partnered CMO facilities. Dupont received an engineering degree from the School of Arts et Métiers of Paris in 1974 and an Aggregation in mechanical engineering in 1987.
Pascale Ehouarn serves as DBV’s Chief Engineering, Manufacturing & Supply Officer, responsible for all manufacturing and supply chain processes, including supervision of Viaskin Peanut’s manufacturing tool, “GEN.4.0”. She is a member of the Executive Committee.
Pascale Ehouarn joined DBV in 2006, playing an instrumental role in designing DBV’s electrospray technology and scaling it up to commercial capacity. Prior to DBV, she was an R&D Project Manager at Unaxis, a Switzerland-based provider of semi-conductor thin film coating equipment by plasma. Pascale Ehouarn holds a PhD in Plasma Physics from the University of Paris XI and also completed a post-doctorate at the University of Karlsruhe in Germany.
Laurent Martin has served as Chief Development Officer since January 2016, and is a member of the Executive Committee. Laurent has held several leadership positions since joining the company in 2007, including Senior Executive Vice President, Product Strategy & Regulatory Affairs and Director of Regulatory Affairs & Quality. Prior to joining DBV, Laurent held various positions at Orphan Europe including Director of Pharmaceutical and Pre-Clinical Development, and Quality Assurance Director together with the role of Interim Responsible Pharmacist (Qualified Person). Earlier in his career, he held roles within Global Regulatory Affairs at Galderma and Guerbet. Laurent received his PharmD from the Université René Descartes in Paris, an M.B.A. from IAE Paris Sorbonne and a Master of Law in Public Health from the faculty of Sceaux
Susanna Mesa serves as DBV’s Chief Business Officer, overseeing strategic positioning and capital markets, including investor relations and corporate affairs. She is a member of DBV’s Executive Committee. Since joining the Company in 2014, Susanna has played an instrumental role in defining and implementing the Company’s global strategy. During her tenure as VP of Finance, Investor Relations & Strategy, Susanna was tasked with expanding DBV’s shareholder base and supporting the listing of the company in the NASDAQ in 2014. She was promoted to SVP, Strategy in 2015. Susanna was previously at the Trout Group, serving as an advisor on capital formation and business development opportunities. Prior to joining Trout, Susanna held positions at the Leukemia and Lymphoma Society and at Jefferies. She graduated Magna Cum Laude from the University of Georgia.
Magali Richard serves as DBV’s Chief Strategy Officer, assisting in the definition and implementation of strategic objectives, overseeing business development and strategic planning. She is a member of the Executive Committee. Magali Richard joined DBV in October 2016 and has been responsible for Business Development and Portfolio Strategy. Prior to DBV, Magali Richard was at the Boston Consulting Group (BCG), where she acted as Principal and member of the Biopharma Practice. Magali Richard has a broad expertise in the pharma industry, including corporate strategy and M&A, R&D portfolio definition, manufacturing strategy or development of innovative partnerships with Pharma and Biotechs. Prior to BCG, she was a Scientist at Biomarin Pharmaceutical. Magali Richard graduated from Ecole Polytechnique in Paris and from Ecole Nationale des Mines de Paris. She also holds a PhD in Molecular Biology from Université Pierre & Marie Curie in France.
Sébastien Robitaille serves as DBV’s Chief Transformation Officer and Deputy Chief Financial Officer, responsible for leading the Company’s operational transformation from a development-stage biotechnology company to a potential commercial organization. He oversees Finance, Information Systems at Group level and Human Resources in France, and is a member of the Executive Committee. Sebastien Robitaille joined DBV in 2015 as Senior Vice President, Group Controller & Information Systems and subsequently was named Deputy Chief Financial Officer. Prior to DBV, he worked at Ipsen for 15 years where he held various roles of increasing responsibility and participated in the company’s IPO. Sebastien Robitaille has extensive experience in the pharmaceutical industry and deep knowledge of performance management, forecasting and business modelling, transformation programs and implementation of strategic information systems. He holds a Bachelor’s Degree in Business Administration-Finance from Paris School of Business.
Dr. Hugh Sampson
Dr. Hugh A. Sampson was appointed Chief Scientific Officer in June 2015 and is a member of the Company’s Scientific Advisory Board. Dr. Sampson maintains his positions as the Director of the Jaffe Food Allergy Institute at Mount Sinai and the Kurt Hirschhorn Professor of Pediatrics, and continues to see patients in clinical practice and direct his basic and translational research programs in food allergy and anaphylaxis. In his role as CSO, Dr. Sampson leads DBV’s research team, pursuing potential new applications of Viaskin for the treatment of food allergies, while also supporting the Company’s clinical development teams. Dr. Sampson is past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Asthma and Immunology. He received his M.D. from the State University of New York at Buffalo School of Medicine and his allergy/immunology fellowship at Duke University.
Dr. Lucia Septién
Dr. Lucia Septién was appointed Chief Medical Officer in July 2016 and is a member of the Company’s Executive Committee. Dr. Septién is responsible for the Company’s clinical development programs, medical affairs, global safety and medical operations and she also has a strategic role in accelerating the development of Viaskin product candidates. Dr. Septién has more than 20 years of experience in the pharmaceutical industry. Prior to joining DBV, Septién was Vice President, Global Neurosciences at Ipsen, responsible for the Medical Strategy of the Botulinum Toxin portfolio. Prior to Ipsen, Dr. Septién served as Vice President of the Specialty Care Business Unit, Europe, at Pfizer. Prior to Pfizer, she served at Wyeth Pharma as Assistant Vice President, Global Neuroscience. Dr. Septién earned her medical degree at the National University of Mexico City, specializing in Psychiatry. She completed her post-graduate training in Nuclear Medicine at the Commisariat de l'Energie Atomique in Saclay, France.